Investors and Media
Press Releases
March 25, 2025
FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy
March 16, 2025
Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
March 14, 2025
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 27, 2025
Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress
February 25, 2025
Scholar Rock to Participate in Upcoming Investor Conferences
February 21, 2025
Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
February 14, 2025
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 10, 2025
